Alzchem Group AG and Crearene AG, have agreed on an exclusive memo of understanding (MOU) for the development and commercialization of Creapure®/creatine-based treatment solutions in dialysis. Dialysis is a treatment method which is applied for patients with a compromised kidney function, and which removes toxins, waste substances and salts from the blood.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
43.8 EUR | -1.35% | +0.68% | +70.38% |
04-30 | Transcript : AlzChem Group AG, Q1 2024 Earnings Call, Apr 30, 2024 | |
04-30 | AlzChem Group AG Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+70.38% | 487M | |
-2.75% | 76.28B | |
+2.20% | 48.18B | |
+3.07% | 33.15B | |
+3.59% | 17.98B | |
-7.69% | 11.88B | |
+12.04% | 11.83B | |
+0.75% | 10.85B | |
+5.44% | 9.92B | |
-5.65% | 8.58B |
- Stock Market
- Equities
- ACT Stock
- News AlzChem Group AG
- Alzchem and Crearene Develop Treatments for the Dialysis Market